Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial

BACKGROUND: Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. METHODS:...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Res
Hoofdauteurs: Seo, Jeongkuk, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Lee, Jae Hoon, Hong, Jun Shik, Lee, Gyeong-Won, Oh, Sung Yong, Lee, Ji-Hyun, Yoon, Dok Hyun, Lee, Won-Sik, Kim, Hyo Jung, Kwak, Jae-Yong, Kang, Hye Jin, Jo, Jae-Cheol, Park, Yong, Lee, Ho Sup, Kim, Hyo-Jin, Suh, Cheolwon
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2017
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641512/
https://ncbi.nlm.nih.gov/pubmed/29043235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2017.52.3.200
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items